Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Wraparound care for patients taking GLP-1 agonists must include assessment of nutritional status to identify the risk of malnutrition, writes Ellen Fallows Food insecurity is increasing, particularly ...

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

An investigation has found at least 74 complaints have been made to hospital managers across England in the past 12 months.